Skip to main content
. 2023 Nov 9;10:2049–2058. doi: 10.2147/JHC.S432134

Figure 1.

Figure 1

Kaplan-Meier curve for progression-free survival (a) and overall survival (b) for all patients receiving combination therapy of HAIC and lenvatinib plus camrelizumab. Kaplan-Meier curves of progression-free survival (c) and overall survival (d) for patients stratified by NLR.

Abbreviation: NLR, neutrophil-to-lymphocyte ratio.